麻豆传媒

Sectors
Yogeeta Jadhav headshot.

Yogeeta B. Jadhav

Senior Technical Specialist 鈥 Chemistry

Yogeeta B. Jadhav

Senior Technical Specialist 鈥 Chemistry

Dr. Yogeeta Jadhav thrives on applying her extensive knowledge of chemistry and leveraging over 15 years of patent practice experience to assist clients in protecting their inventions. Her wide-ranging experience includes preparation and prosecution of patent applications; patentability assessment; freedom-to-operate, non-infringement, and patent validity analysis; and due diligence matters spanning a broad spectrum of technologies, including pharmaceuticals, nutraceuticals, chemical compositions and processes, small molecules, vaccines, antibody-drug conjugates, drug formulations, cannabis, food and beverages, personal care products, batteries, pet products, coating and polymers. She is a member of the Firm鈥檚 Intellectual Property Department, Health Care & Life Sciences Sector, and Chemical, Biotechnology & Pharmaceutical Practice.

Prior to joining 麻豆传媒, Yogeeta was a patent scientist at Sandoz India Pvt Ltd, the generic pharmaceuticals division of Novartis. She also worked as a research manager with Lupin Limited, a leading global pharmaceutical company based in Pune, India, where she assisted attorneys with respect to drafting, filing, and prosecuting patent applications; conducting infringement analysis; and evaluating new drug molecules for their patent situation, chemistry, process and technical complexity, and polymorph issues.

After completing her doctoral degree, Yogeeta was a postdoctoral fellow at Monash University in Australia, where she continued her doctoral research focused on the development of a catalytic process for the hydration of aromatic epoxides and phase transfer catalytic reactions in the organic process industry, including agrochemicals, pharmaceuticals, and perfumes, respectively. Her research has resulted in several journal publications and has been presented at national and international conferences.

Presentations and Publications

  • 鈥淩ole of the Omega Phase in the Analysis and Intensification of Solid-Liquid Phase-Transfer-Catalyzed Reactions,鈥 Jadhav, Y.; Yadav, G., Langmuir, 18 (16), 5995鈥6002, 2002
  • 鈥淪ynthesis of 2, 4-dichlorophenoxyacetic acid: Novelties of Kinetics of Inverse Phase Transfer Catalysis,鈥 Jadhav, Y.; Yadav, G., J. Mol Catalysis A: Chemical, 184 (1鈥2), 151鈥160, 2002
  • 鈥淜inetics and Modeling of Liquid-Liquid Phase Transfer Catalyzed Synthesis of p-chlorophenyl acetonitrile: Role of Co-catalyst in Intensification of Rates and Selectivity,鈥 Jadhav, Y.; Yadav, G., J Molecular Catalysis A: Chemical, 192, 41鈥52, 2003
  • 鈥淐ascade Engineered Phase Transfer Catalysis: A Novel Concept in Green Chemistry,鈥 Jadhav, Y.; Yadav, G., Clean Tech. Environ. Policy, 6(1), 32鈥42, 2003
  • 鈥淣ovelties of Solid-Liquid Phase Transfer Catalyzed Synthesis of I-isopropyl-p-chlorophenyl acetonitrile from pchlorophenyl acetonitrile,鈥 Jadhav, Y.; Yadav, G., Organic Process Research & Development, 7(4), 588-598, 2003
  • 鈥淣ovelties of Kinetics and Mechanism of Liquid-Liquid Phase Transfer Catalyzed Reduction of p-nitroanisole to p-anisidine,鈥 Jadhav, Y.; Yadav, G.; Sengupta, S., Chem. Engg. Science, 55(12), 2681鈥2689, 2003
  • 鈥淪electively Engineered Phase Transfer Catalysis in the Synthesis of Fine Chemicals: Reactions of p-chloronitrobenzene with sodium sulphide,鈥 Jadhav, Y.; Yadav, G.; Sengupta, J. Molecular Catalysis A: Chemical, 200, 117鈥129, 2003

Languages

  • Hindi (fluent)
  • Marathi (native)
July 10, 2025 Deals and Wins

麻豆传媒 Represents Verona Pharma in $10B Acquisition by Merck

麻豆传媒 acted as U.S. intellectual property counsel for UK-based Verona Pharma, a biopharmaceutical company focused on respiratory diseases, in its approximately $10 billion acquisition by Merck & Co. Inc. (Merck).
June 24, 2024 PharmaPatents

USPTO Publishes Drug Patent and Exclusivity Study Report

The U.S. Patent and Trademark Office in conjunction with the Food and Drug Administration, and in response to January and April 2022 letters from Senator Thom Tillis, has published a report examining the time from approval of a New Drug Application until the first generic launch for 25 drug products, including consideration of patent and regulatory exclusivities.
May 16, 2023 Blogs

Federal Circuit Considers Patentability of Overlapping Ranges

In UCB Inc. v. Actavis Laboratories UT Inc., the Federal Circuit affirmed the district court鈥檚 judgement of invalidity on obviousness grounds but reversed the finding of anticipation.
Curved modern glass building facade with vertical and horizontal lines, featuring the 麻豆传媒 logo in the lower right corner鈥攁n impressive corporate law office recognized for its lawyers in Chicago.
March 14, 2023 Blogs

USPTO Discusses Duty of Disclosure and Duty of Reasonable Inquiry

On February 23, 2023, the U.S. Patent and Trademark Office held a virtual panel discussion on the duty of disclosure and duty of reasonable inquiry.
January 30, 2023 Blogs

USPTO-FDA Listening Session 鈥 Voices from Patient and Patent Advocates

On January 19, 2023, the U.S. Patent and Trademark Office (USPTO) and Food and Drug Administration (FDA) held a 鈥渓istening session鈥 focusing on USPTO-FDA collaboration initiatives proposed pursuant to President Biden's Executive Order on 鈥淧romoting Competition in the American Economy鈥 to 鈥減romote greater access to medicines for American families.鈥
A close-up view of various pills and capsules in different shapes, sizes, and colors鈥攊ncluding white, blue, yellow, and beige鈥攕cattered together, as often seen in cases handled by law offices or lawyers in Chicago.
May 15, 2018 Blogs

Claim Construction Of An Enantiomeric Chemical Structure

In <EM>Sumitomo Dainippon Pharma Co. V. Emcure Pharm. Ltd</EM>., the Federal Circuit affirmed the district court鈥檚 decision that construed a chemical structure as reading on the lurasidone enantiomer that is the active ingredient of Latuda庐.